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Abstract
Background: Concussions account for the majority of traumatic brain injuries (TBI) and can result in cumulative
damage, neurodegeneration, and chronic neurological abnormalities. The underlying mechanisms of these
detrimental effects remain poorly understood and there are presently no specific treatments for concussions.
Neuroinflammation is a major contributor to secondary damage following more severe TBI, and recent findings
from our laboratory suggest it may be involved in the cumulative properties of repeated concussion. We previously
found that an anti-CD11d monoclonal antibody that blocks the CD11d/CD18 integrin and adhesion molecule
interaction following severe experimental TBI reduces neuroinflammation, oxidative activity, and tissue damage, and
improves functional recovery. As similar processes may be involved in repeated concussion, here we studied the
effects of the anti-CD11d treatment in a rat model of repeated concussion.
Methods: Rats were treated 2 h and 24 h after each of three repeated mild lateral fluid percussion injuries with
either the CD11d antibody or an isotype-matched control antibody, 1B7. Injuries were separated by a five-day interinjury interval. After the final treatment and either an acute (24 to 72 h post-injury) or chronic (8 weeks post-injury)
recovery period had elapsed, behavioral and pathological outcomes were examined.
Results: The anti-CD11d treatment reduced neutrophil and macrophage levels in the injured brain with
concomitant reductions in lipid peroxidation, astrocyte activation, amyloid precursor protein accumulation, and
neuronal loss. The anti-CD11d treatment also improved outcome on tasks of cognition, sensorimotor ability, and
anxiety.
Conclusions: These findings demonstrate that reducing inflammation after repeated mild brain injury in rats leads
to improved behavioral outcomes and that the anti-CD11d treatment may be a viable therapy to improve postconcussion outcomes.

Introduction
Concussions account for the majority of all traumatic brain
injuries (TBI) and are now recognized as a serious global
health concern, particularly in individuals at an increased
risk of suffering concussion, such as athletes and military
personnel [1-3]. Although the effects of a single concussion
are often transient [3], repeated concussion has been
associated with cumulative [4,5] and chronic neurological
disturbances including cognitive deficits, emotional
abnormalities, motor impairments, and neurodegenerative
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disease [6-10]. However, little is known about the factors
and mechanisms that might contribute to these debilitating
effects, and no specific treatment options currently exist
[3,10-12]. In light of this, our laboratory has recently used
repeated mild lateral fluid percussion injuries (mLFP) in the
rat as a novel model of repeated concussion [5]. This work
demonstrated that repeated mLFP induces cumulative
long-term behavioral impairments and cortical damage
consistent with those observed in the clinical population,
and suggests that neuroinflammation may be associated
with these effects.
Neuroinflammation is known to be a key mediator of
secondary injury in moderate and severe TBI [13,14], as
well as other neurodegenerative disorders [15]. The
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neuroinflammatory response in TBI is characterized by
the activation of microglia and astrocytes, the release of
pro-inflammatory cytokines and chemokines, and the
infiltration of peripheral leukocytes across the blood–brain
barrier and into the injured brain [14,16,17]. Infiltrating
leukocytes further drive the neuroinflammatory response
and exacerbate secondary injury through the production of pro-inflammatory mediators, free radicals, lipid
peroxidation, and oxidative stress [14,18-20]. The
infiltration of leukocytes into the CNS is mediated, in part,
by CD11/CD18 integrins, a family of membrane-bound
glycoproteins. The CD11/CD18 heterodimer is composed
of a common CD18 subunit and one of four CD11
subunits (a to d). The CD11d/CD18 integrin is expressed
on neutrophils and monocytes/macrophages, and
binds to the adhesion molecule vascular cell adhesion
molecule-1(VCAM-1) expressed on the surface of
vascular endothelial cells in both rat and human CNS
[21,22]. Previous work from our laboratory has used a
CD11d monoclonal antibody (mAb) to block the
CD11d/CD18-VCAM-1 interaction following spinal
cord injury and after single severe fluid percussion
injury in rats [18,23]. The anti-CD11d treatment
reduced leukocyte levels in the injured brain with
concomitant reductions in astrocyte activation, lipid
peroxidation, axonal injury, and neuronal loss [18].
Further, the reduced neuroinflammation in antiCD11d mAb-treated rats was accompanied by improved
performance on behavioral tasks of cognition, anxiety-like
behavior, and sensorimotor ability relative to injured rats
treated with a control mAb. Since neuroinflammation may
also be implicated in concussion [24], and occurs following
mLFP [5,24-26], here we evaluated the effects of the
CD11d mAb treatment in the repeated mLFP rat
model of repeated concussion. We report that treatment with the CD11d mAb after each of three
repeated mLFP reduced neutrophil and macrophage
numbers, astrocyte activation, and lipid peroxidation.
These reductions in mediators of secondary injury
were accompanied by reductions in neuronal loss,
axonal injury, and behavioral deficits.
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Materials and methods
Subjects

All procedures and behavioral tests were in accordance
with guidelines of the Canadian Council on Animal Care
and approved by the University of Western Ontario
Animal Use Subcommittee. Subjects were 87 young
adult male Long-Evans hooded rats obtained from
Charles River Laboratories (Quebec, Canada). Prior to
surgery rats weighed between 250 to 300 g, and were
naïve to all experimental procedures. After surgery rats
were housed individually for the remainder of the study
under a 12:12 light/dark cycle and were allowed access
to food and water ad libitum.
Treatment groups

Rats were randomly assigned to one of three treatment
groups: three sham injuries + saline treatment (sham),
three mLFP + isotype-matched control mAb (1B7), and
three mLFP + CD11d mAb treatment (CD11d). Rats
received their assigned treatments 2 h and again 24 h
after each injury via tail vein injection (1.0 mg/kg; [18]).
This dosing schedule is based on the dosing schedule that
we have used successfully to treat both spinal cord-injured
rats and mice [27,28]. Rats had a 5-day inter-injury recovery period between repeated injuries [5]. After the final
treatment, rats were designated to one of two recovery
periods: short-recovery (SR, 24 hours post-injury), or
long-recovery (LR, 8 weeks post-injury). Thus, there
were a total of six experimental groups in the current
study: sham-SR (n = 15), 1B7-SR (n = 15), CD11d-SR
(n = 15), sham-LR (n = 12), 1B7-LR (n = 12), and
CD11d-LR (n = 12). The timeline for the experimental
protocol is outlined in Figure 1.
Surgery and injuries

Surgeries and injuries were carried out as previously
described [5,25,26]. Under anesthesia and aseptic
conditions, rats underwent a craniotomy (3 mm)
centered over the following coordinates with reference to
Bregma: anterior/posterior −3.0 mm, medial/lateral 6.0
mm. A hollow plastic injury cap was sealed over the

Figure 1 Experimental timeline. Rats received either three sham injuries or three mild lateral fluid percussion injuries. After each injury rats
were injected with their assigned treatment at 2 h and 24 h post-injury. After the final treatment, rats had either a short- (24 h) or long- (8 weeks)
recovery period before behavioral testing. After behavioral testing, rats were sacrificed for histochemical and biochemical analyses.
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craniotomy and a removable plug was inserted into the
injury cap to seal the craniotomy until, and after, mLFP
was administered. Approximately 24 h post-surgery rats
were placed under anesthetic and the rat was attached to
the injury device. At the first response of hind-limb withdrawal to a toe pinch, rats in the CD11d and 1B7 groups
received a single mLFP with a force of 1 to 1.5 atm.
Sham-injured rats were treated identically but were
removed from the injury device without receiving a
mLFP. Apnea, time of unconsciousness, and self-righting
reflex were all monitored immediately after each injury to
assess acute injury effects. Rats received tail vein injections
of the assigned treatments 2 h and 24 h after each injury.
Rats were given a 5-day inter-injury recovery period
before undergoing the identical injury procedure as
described above for the remaining two injuries. After their
final drug injection, rats were assigned to either a 24 h
(SR) or 8 week (LR) recovery condition.
Histochemical and biochemical analyses of brains
Tissue preparation

For histological examination at 72 h after the final injury,
approximately half of the rats (n = 6 to 7 for each group)
were anesthetized (2.5 g/kg urethane) and perfused
transcardially with saline, followed by 4% paraformaldehyde
in PBS (pH 7.2 to 7.4). Brains were removed, post-fixed for
24 h at 4 C, cryoprotected in increasing concentrations of
sucrose, and sectioned into 35-μm cross-sections for
immunohistochemical staining. The entire brain was
sectioned coronally and floating sections containing a
visible hippocampus (approximately 3 mm caudal to
Bregma) were saved for immunohistochemical staining. For
biochemical assays and western blotting, approximately half
of the rats (n = 6 to 7 for each group) at 72 h and 8 weeks
post-injury were perfused with cold 0.9% NaCl and their
brains removed. The brainstem and cerebellum were
removed and the middle third of the injured hemisphere
homogenized and stored at −80 C [18].
Immunohistochemistry and histology

Monoclonal mouse antibodies, anti-ED1 (1:500, Serotec,
Raleigh, NC, USA), anti-NeuN (1:500, EMD Millipore
Corporation, Billerica, MA, USA), anti-Glial Fibrillary
Acidic Protein (GFAP, 1:500, Sigma, St. Louis, MO,
USA) and anti-APP (1:200, Sigma), and polyclonal rabbit
anti-neutrophil antibody (1:20000, gift of Dr. Daniel
Anthony, Oxford University, Oxford, UK), were used for
immunohistochemical staining. Immunoreactivity was
revealed with a glucose-diaminobenzidine-nickel solution. Representative sections of the injured area from
each animal were processed free-floating for staining as
described previously [18]. Fields of view were captured
digitally by a Retiga 1300 camera (Quantitative Imaging
Corporation, Burnaby, BC, Canada), and ImagePro Plus
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Software (Media Cybernetics, Silver Spring, MD, USA).
Photomicrographs were captured from coronal sections
deemed by inspection of the tissue structure to be at the
site of injury. A 20× field of view of the cortex above the
hippocampus was sampled. Cells were counted visually
and an average number from three sections was
calculated for each animal. Because sections were
sampled from a group of floating sections, stereological
methods for counting were not used.
Neutrophil, macrophage and neuronal cell counts in
shams (n = 5), 1B7 controls (n = 4) and anti-CD11d
-treated (n = 4) rats at 72 h after the third injury were done
by counting the number of cells immunoreactive for the
anti-neutrophil, anti-ED1 and anti-NeuN antibodies,
respectively. The analyses were done blinded to the injury
or treatment of the rats. The 20× fields of view selected for
counting neutrophils and macrophages were those with
the greatest density of inflammatory cells. Approximately
the same field of view on a different section in each
animal was used to count cells immunoreactive for
NeuN. Using a similar protocol the area of GFAP
immunoreactivity was also quantified in these rats at
the same time point. In three sections, fields of view
(20×) were again selected that approximated the same
region analyzed for inflammatory cells and area per
area measurements of GFAP immunoreactivity were
obtained and averaged. When no cortical injury or
inflammatory cells were apparent, fields of view were
selected from the same location as in the other rats.
Western blotting analysis

Tissue sample preparation and protein determination were
performed as described previously [18]. Primary antibodies
used included: anti-ED1 (1:1000, Serotec), anti-GFAP
(1:5000, Sigma), anti-neutrophil (1:20000), anti-NeuN
(1:5000, EMD Millipore), anti-APP (1:2000, Sigma) and
anti-β-actin (1:10000, Sigma). Signal detection was
facilitated with enhanced chemiluminescence (ECL kit,
Amersham, Piscataway, NJ, USA). Immunoreactive bands
were scanned by an imaging densitometer (BioRad GS-700
Imaging Densitometer) and the results were quantified
using Multi-Analyst software (Bio-Rad). Densitometric
values were normalized for protein loading using β-actin as
a loading control [18].
Myeloperoxidase (MPO) activity assay

MPO enzymatic activity is derived mostly from
neutrophils and to a lesser extent from macrophages.
This activity, an estimate of the extent of neutrophil
infiltration/activation and macrophage activation, was
measured as described previously [18]. MPO activity was
calculated using a standard curve prepared with purified
human MPO (Sigma). Results are expressed as units
per mg protein.
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Measurement of lipid peroxidation

The relative levels of aldehydes including malondialdehyde
(MDA), indicators of lipid peroxidation, were measured
using thiobarbituric acid reactive substances (TBARS)
assay as described previously [18,29]. MDA bis (dimethyl
acetal; Sigma) was used as a standard, and the level of lipid
peroxide was expressed as nmol of TBARS.
Behavioral testing
Water maze

Behavioral testing spanned 2 days, beginning 24 h after
the final treatment for SR rats and 8 weeks after the final
treatment for LR rats. Spatial cognition was assessed
using a water maze as described previously [18,25].
Acquisition training consisted of 10 trials with a
maximum time of 60 s and occurred immediately after
elevated-plus maze testing. Reversal training was carried
out 24 h after acquisition and consisted of 10 trials with
the hidden escape platform located in the opposite
quadrant of the acquisition session. Water maze
behavior was analyzed by a tracking system that digitized
each swim trial (Poly-Track, San Diego Instruments, San
Diego, CA, USA). Search latency and direct and circle
swims were used as measures of spatial place memory in
the water maze. Swim speed was used as a measure of
motor ability. For graphic presentation of search time
data in Results, the time to reach the platform was
averaged for every block of two trials (for example,
block 1 = (trial 1 + trial 2)/2).
Elevated plus maze

Anxiety-like behavior was assessed using an elevated-plus
maze as described previously [18,25]. Rats were first placed
in the center of the elevated-plus maze facing an open arm
and allowed to explore the maze freely for 5 minutes.
Following testing, a videotape of the trial was scored by a
person blind to treatment group. As time spent in the open
arm is decreased in rats that exhibit greater anxiety-related
behaviors, a percentage score was calculated for the
time spent in the open arm as follows: time in the
open arm/(time in the open arm + time closed arm)
[25,30]. The number of closed arm entries was also
calculated as a measure of locomotion [31,32]. All four
paws had to enter an arm for it to be considered an entry.
Beam task

After the completion of water maze reversal testing,
sensorimotor ability was evaluated using a narrow
wooden beam 1 m long and 2 cm wide as described
previously [18,25]. A video camera recorded all trials.
After testing, the videotape was scored by an individual
who was blind to group membership to determine
traverse times and the number of slips and falls. Traverse
time was defined as the time required to cross the 1 m
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long beam, with a maximum allowed time of 60 s. Slips
and falls were scored when any limb slipped from the
beam, or the rat fell off the beam. Rats that fell from the
beam were given a maximum time of 60 s.
Statistical analyses

Water maze search time and beam traverse time data
were analyzed by SPSS 17.0 using mixed design analysis
of variance (ANOVA) with treatment group as the
between-subjects factor and trial as the within-subjects
factor. One-way ANOVA, with treatment group as the
between-subjects factor, were used to analyze acute
injury measures, percent of time in open arm, closedarm entries, direct and circle swims, swim speed, and
slips and falls. Fisher’s least significant difference (LSD)
post hoc pair-wise comparisons were carried out on
behavioral data when appropriate. Histochemical and
biochemical results were analyzed using randomized
one-way ANOVA. Student Neuman Keuls post hoc tests
were carried out for these analyses when appropriate.
Statistical significance was set at P ≤0.05. Throughout
the Results, the values from the ANOVA are presented
in the text. Statements of differences between mean
values and indications of significance on the figures
assume P-values ≤0.05 in the post hoc tests.

Results
Acute injury measures

Measures of the rats’ acute recovery from the mLFP
were analyzed statistically after the final assigned (third)
injury. The duration of apnea after mLFP did not
differ between groups (F2,78 = 1.879, P = 0.160)
(Figure 2A). The duration of unconsciousness (F2,78 =
30.762, P <0.001) (Figure 2B) and time required for selfrighting (F2,78 = 36.143) P <0.001) (Figure 2C) were
significantly increased in both the 1B7 and CD11d
groups compared to the sham-injured group. Treatment
with the CD11d mAb significantly improved the rats’
acute recovery as the CD11d group had shorter periods of
unconsciousness and self-righting reflex times than
the 1B7 group.
Histochemical and biochemical findings at 72 h and 8
weeks after repeated mild fluid percussion injury
Neutrophils

We assessed the effect of the anti-CD11d treatment on
neutrophil infiltration at 72 h and 8 weeks post-injury by
immunostaining brain sections with an antibody to a 56
kDa protein expressed by neutrophils [18,33]. Sham
brains contained very few neutrophils (Figure 3A, panels
1 and 4), whereas many neutrophils were detected near
the repeated mLFP site in the cortex of the 1B7-treated
rats (Figure 3A, panels 2 and 5). The density of these
cells appeared reduced in the anti-CD11d-treated rats,
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(Figure 3A, panels 3 and 6). An indirect measure of
neutrophil density in the brain was quantified using
the anti-neutrophil antibody in a western blot analysis
(Figure 3B). At 72 h post-injury, MPO activity was
low in homogenates from sham-injured rats but significantly increased in the two repeated mLFP groups
(F2,16 = 15.265, P <0.001). The neutrophil protein
expression in the brain homogenates of the CD11d
mAb-treated rats at this time was significantly less
than in the 1B7 mAb-treated controls (F2,15 = 10.209,
P <0.01). Direct neutrophil cell counts (anti-neutrophil
immunoreactive cells) confirmed these findings revealing
an average of 2.3 ± 1.2, 185.0 ± 77.0 and 2.3 ± 1.0
neutrophils per 20× field located at the lesion in shams,
1B7 controls and anti-CD11d-treated rats, respectively.
The differences in cell counts between the CD11d- and
1B7-treated groups and between the shams and the 1B7
group were statistically significant (F2,10 = 6.48, P <0.05,
Student Neuman Keul test, P <0.05). At 8 weeks postinjury, neutrophil protein expression was not significantly
different between CD11d- and 1B7-mAb-treated rats.
The effect of the anti-CD11d treatment was also assessed
on MPO enzymatic activity, a measure of neutrophil infiltration/activation and, to a lesser degree, of macrophage
activation (Figure 3C). At 72 h post-injury, MPO activity
was low in homogenates from sham-injured rats but
significantly increased in the two repeated mLFP groups
(F2,16 = 15.265, P <0.001). Anti-CD11d-treated rats had
significantly less MPO activity compared to the control
1B7-treated rats. MPO activity was minimal in all groups
at 8 weeks post-injury.
Microglia/macrophages

Figure 2 Anti-CD11d treatment improves recovery in the acute
period after repeated mild fluid percussion injury. Treatment
group of rats in panels A-C is indicated by the legend in panel A
(n = 27/group). (A) Plot of duration of apnea following the final
(third) injury. (B) Plot of duration of unconsciousness following the
final injury. (C) Plot of time required for self-righting following the
final injury. Histogram bars represent means (± standard error of the
mean). *Different from sham-injured group; #different from 1B7
group. For post hoc comparisons of means, all P ≤0.05. For
additional statistical details see Results.

The effect of the anti-CD11d treatment on microglia/
macrophage populations was assessed at 72 h and 8
weeks post-injury by immunostaining brain sections
with an antibody to ED-1 (Figure 4). Only a few ED-1
immunoreactive cells were present in the brains of
sham-injured rats (Figure 4A, panels 1 and 4). The size
and number of ED-1 cells was clearly increased in the
1B7 rats (Figure 4A, panels 2 and 5). These cells had the
rounded morphology typical of macrophages and
activated microglia and they were distributed from the
superficial cortical layers through to the deeper layers.
In the brains of CD11d mAb-treated rats, the density of
the ED-1 macrophages appeared reduced (Figure 4A,
panels 3 and 6). The presence of microglia/macrophages
was quantified indirectly using western blot analysis for
ED-1 (Figure 4B). At 72 h post-injury, ED-1 expression
(110 kDa band) was low in the brain homogenates of
sham-injured rats but increased significantly in the two
repeated mLFP groups (F2,15 = 10.769, P = 0.001). Direct
macrophage cell counts (anti-ED1 immunoreactive cells)
confirmed these findings revealing an average of 28.5 ±
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Figure 3 Neutrophil infiltration after repeated mild fluid percussion injury is reduced by the anti-CD11d treatment. (A)
Photomicrographs of brain sections at the cortical injury site, or a comparable site in the sham-injured rats, immunostained by an anti-neutrophil
antibody. The sections from sham-injured, 1B7 and anti-CD11d-treated rats at 72 h after injury are shown at lower power in panels 1 to 3 and
higher power in panels 4 to 6. Scale bars = 100 μm. Scale bar in panel 3 refers to panels 1 to 3. Scale bar in panel 6 refers to panels 4 to 6. (B)
MPO activity in brain homogenates in sham-injured groups (n = 6, both times), 1B7 groups (n = 7 and 6, respectively), and CD11d groups (n = 6
and 5 respectively) at 72 h and at 8 weeks post-injury. A.U., arbitrary units; *different from sham-injured group; #different from 1B7 group; all P ≤0.05 except
that the gray *indicates P = 0.067. (C). Neutrophil protein, identified by western blotting in brain homogenates expressed as mean values ± standard error
of the mean, with a representative autoradiogram shown above each set of histograms (n = 6 for each group).

10.7, 343.0 ± 73.7 and 43.4 ± 5.8 macrophages per 20×
field located at the lesion in shams, 1B7 controls and
anti-CD11d-treated rats, respectively. The differences in
cell counts between the CD11d- and 1B7-treated groups
and between the shams and the 1B7 group were
statistically significant (F2,10 = 19.88, P <0.001, Student

Neuman-Keuls test, P <0.05). At 8 weeks post-injury,
ED-1 expression increased only in the brain
homogenates of the 1B7-treated rats. ED-1 expression in
anti-CD11d-treated rats did not differ from shams and
tended to be lower than that of the 1B7-treated controls
(P = 0.073).
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Figure 4 Macrophages in the brain after repeated mild fluid percussion injury are reduced by the anti-CD11d treatment. (A)
Photomicrographs of brain sections at the injury or equivalent site at 72 h after injury in the cortex in sham-injured, 1B7 control and anti-CD11d
-treated rats immunostained by an anti-ED1 antibody. Format is similar to that described for Figure 3. Scale bars = 100 μm. (B) Macrophage protein,
identified by western blotting in brain homogenates expressed as mean values (± standard error of the mean) with a representative autoradiogram
shown above each set of histograms. Macrophage protein is shown at 72 h and 8 weeks in sham-injured, 1B7 and anti-CD11d groups (n = 6 all
groups). A.U., arbitrary units; *different from sham group; #different from 1B7 group; all P ≤ 0.05 with the exception that gray # indicates P = 0.073.

GFAP

The effect of the anti-CD11d treatment on astrocyte activation in the sham-injured, 1B7, and CD11d rats was assessed
by immunohistochemistry using the GFAP antibody on
brain sections (Figure 5). GFAP staining demonstrated
increased astrogliosis with densely stained astrocytes
bearing long, overlapping hypertrophic processes in the
brains of the 1B7 rats (Figure 5A, panels 2 and 5) compared
to similar sections from CD11d-treated or sham-injured
rats (Figure 5A panels 1, 3, 4, and 6). GFAP levels were
quantified by western blot analysis (Figure 5B). GFAP
(approximately 50 kDa) expression was significantly

lower in CD11d-treated rats compared to 1B7-treated
rats at 72 h and 8 weeks post-injury (72 h: F2,15 =
14.144, P <0.001; 8 weeks: F2,15 = 8.02, P <0.01).
Evaluating the area of GFAP immunoreactivity at the
lesion epicenter confirmed the western blot findings
at 72 h revealing an average area of immunoreactivity
of 0.012 ± 0.001, 0.22 ± 0.03 and 0.15 ± 0.02 percent
(as percent of total area in a 20× field located at the
lesion) in shams, 1B7 controls and anti-CD11d-treated
rats, respectively. The differences in percent area of
GFAP immunoreactivity between the CD11d- and
1B7-treated groups and between the shams and the
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Figure 5 Astrogliosis assessed by the expression of glial fibrillary acidic protein (GFAP) in the brain after repeated mild fluid
percussion injury is reduced by the anti-CD11d treatment. (A) Photomicrographs of brain sections at the location of cortical injury or
equivalent site, at 72 h after injury, immunostained by an antibody to GFAP. Format is as in Figure 3. Scale bars = 100 μm. (B) GFAP, identified by
western blotting in brain homogenates, shown at 72 h and 8 weeks in sham-injured, 1B7, and anti-CD11d groups (n = 6, all groups). A.U.,
arbitrary units; *different from sham-injured group; #different from 1B7 group; all P ≤0.05.

1B7 group were statistically significant (F2,10 = 30.47,
P <0.001, Student Neuman-Keuls test, P <0.05). At 8
weeks post-injury GFAP levels as determined by
western blot analyses in the CD11d-treated rats were
not different from shams.
Neuronal survival

The effect of the anti-CD11d treatment on neuronal survival was assessed by immunostaining with an antibody
to NeuN (Figure 6). NeuN staining in the cortex of sham
brains was dense (Figure 6A, panels 1 and 4), whereas
staining was less intense near the cortical injury site in
1B7-treated rats (Figure 6A, panels 2 and 5). After antiCD11d treatment, the density of these cells appeared
more like that in the sham-injured rats (Figure 6A,
panels 3 and 6). To provide an indirect quantification of
neuronal survival, western blotting for the marker NeuN

was done using the brain homogenates (Figure 6B). At
72 h post-injury, densitometry demonstrated that
although both injured groups had lower levels of NeuN
than sham-injured rats, the anti-CD11d mAb-treated
rats had greater levels of NeuN expression than the 1B7
controls (F2,15 = 11.009, P = 0.001). Direct neuronal cell
counts (anti-NeuN immunoreactive cells) confirmed
these findings revealing an average of 409 ± 22.1, 155
± 93.3 and 382 ± 13.2 neurons per 20× field located
at the lesion in shams, 1B7 controls and anti-CD11d
-treated rats, respectively. The differences in cell
counts between the CD11d- and 1B7-treated groups
and between the shams and the 1B7 group were
statistically significant (F2,10 = 7.07, P <0.05, Student
Neuman-Keuls test, P <0.05). At 8 weeks post-injury,
NeuN expression decreased significantly in both
repeated mLFP groups (F2,15 = 9.142, P <0.01).
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Figure 6 Neuronal loss assessed by expression of the neuronal protein NeuN in the brain after repeated mild fluid percussion injury is
decreased by the anti-CD11d treatment. (A) Photomicrographs of brain sections at the cortical injury site or equivalent region, at 72 h after
injury, immunostained by an antibody to NeuN. Format is as in Figure 3. Scale bars = 100 μm. (B) NeuN, identified by western blotting in brain
homogenates, is shown at 72 h and 8 weeks in sham-injured, 1B7, and anti-CD11d groups (n = 6, all groups). A.U., arbitrary units; *different from
sham-injured group; #different from 1B7 group; all P ≤0.05 with the exception that gray # indicates P = 0.066.

However, a non-significant trend suggested that the
NeuN expression in anti-CD11d-treated rats was
greater than that in the 1B7 controls (P = 0.066).
Amyloid precursor protein (APP)

APP accumulation in white matter after TBI is an indicator of axonal injury [25,34]. As the corpus callosum is

commonly affected by TBI [34], and contains a high
density of intercortical axon projections, the effect of the
anti-CD11d treatment on APP accumulation in the
corpus callosum was assessed by immunostaining with
an antibody to APP (Figure 7). APP accumulated minimally in the brains of sham-injured rats (Figure 7A,
panels 1 and 4) but was clearly increased in the 1B7
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control rats (Figure 7A panels 2 and 5). APP appeared
to accumulate to a lesser extent in the brains of antiCD11d-treated rats (Figure 7A panels 3 and 6). APP
expression was quantified in rat brain homogenates
using western blot analysis (Figure 7B). APP expression (90 kDa) increased significantly with repeated
mLFP at 72 h (F2,15 = 17.828, P <0.001) and 8 weeks
post-injury (F2,15 = 17.629, P <0.001). However, at
both time points, APP expression was lower in the
anti-CD11d treatment groups than in the 1B7 controls.
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nmol/mg protein) was significantly less than in the brain
homogenates of the 1B7 mAb-treated controls (56.1 ± 4
nmol/mg protein) and not different from the sham-injured
rats (34.2 ± 3.3 nmol/mg protein) (F2,16 = 14.072, P <0.001,
Student Neuman-Keuls test, P <0.05). By 8 weeks postinjury, lipid peroxidation was increased in both repeated
mLFP groups above values in sham-injured rats (F2,14 =
6.658, P <0.01, Student Neuman-Keuls test, P <0.05).

Lipid peroxidation

Behavioral findings after repeated mild fluid percussion
injury
Water maze

An indication of lipid peroxidation due to free radical tissue
damage and/or to activation of the arachidonic acid cascade
was evaluated by a TBARS assay that measures the relative
levels of MDA and other aldehydes in tissue homogenates.
At 72 h post-injury, lipid peroxidation in the brain
homogenates of the CD11d mAb-treated rats (33.3 ± 3

Search time and the percentage of direct and circle
swims in the water maze were used as measures of
spatial cognition. Swim speed was used as a measure of
locomotion. In the SR condition, both acquisition and
reversal search times decreased in all groups as testing
progressed (acquisition: trial F9,369 = 22.034, P <0.001,

Figure 7 White matter injury measured by the increase in amyloid precursor protein (APP) expression in the brain after repeated mild
fluid percussion injury is reduced by the anti-CD11d treatment. (A) Photomicrographs of brain sections at the center of the corpus callosum,
72 h after injury, immunostained by an antibody to APP. Format is as in Figure 3. Scale bars = 100 μm. (B) APP, identified by western blotting in
brain homogenates, is shown at 72 h and 8 weeks in sham-injured, 1B7, and anti-CD11d groups (n = 6, all groups). A.U., arbitrary units; *different
from sham-injured group; #different from 1B7 group; all P ≤0.05.
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Figure 8A; reversal: trial F9,369 = 13.799, P <0.001,
Figure 8C). However, the CD11d rats had shorter
search times than the 1B7 rats and did not differ from the
sham group, whereas the 1B7 rats had longer search times
than shams (acquisition: treatment F2,43 = 5.795, P <0.01,
Figure 8A; reversal: treatment F2,43 = 6.016, P <0.01,
Figure 8C). The SR direct and circle swim data were
consistent with the search time data. They revealed more
direct and circle swims in the CD11d group than in the
1B7 group during both acquisition and reversal, no difference between the CD11d rats and shams, and significantly
fewer direct and circle swims in the 1B7 group than in
sham-injured rats (acquisition: F2,43 = 6.161, P <0.01,
Figure 8B; reversal: F2,43 = 5.727, P <0.01, Figure 8D). Swim
speed did not differ between the groups (all P >0.05; data
not shown).
In the LR condition both acquisition and reversal
search times decreased in all groups as testing
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progressed (acquisition: trial F9,297 = 14.962, P <0.001,
Figure 9A; reversal: trial F9,297 = 7.198, P <0.001;
Figure 9C). However, the CD11d rats had shorter search
times than the 1B7 rats, although both remained different from shams (acquisition: treatment F2,33 = 9.057,
P <0.001, Figure 9A; reversal: treatment F2,33 = 7.415,
P <0.01, Figure 9C). No significant group differences in
direct and circle swims were detected between the groups
during acquisition (P >0.05; Figure 9B), whereas both
CD11d and 1B7 rats had fewer direct and circle
swims compared to sham-injured rats during reversal
(F2,35 = 9.680, P <0.001, Figure 9D). The groups did
not differ with respect to swim speed (P >0.05; data
not shown).
Elevated-plus maze

Time spent in the open arms of the elevated-plus
maze was used to measure anxiety-like behavior. The

Figure 8 Anti-CD11d treatment improves cognitive performance in the water maze in the short recovery period (24 h) after repeated
mild fluid percussion injury. Treatment groups for panels A-D are defined in the legend in panel A (n = 15/group). (A) Plot of search time vs.
sequential trial during acquisition training in the water maze test. Each block is the average of two trials for each rat and data points are mean ±
standard error of the mean (SEM) for the group of rats. (B) Plot of percent of direct and circle swims during acquisition training. Histogram bars
represent means of data for the groups of rats collected during the 10 trials (± SEM). (C) Plot of search time with respect to number of trials
(as in A) during reversal training. (D) Plot of percent of direct and circle swims during reversal training. *Different from sham-injured group;
#different from 1B7 group; for post hoc comparisons of means, all P ≤0.05. For additional statistical details see Results.
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Figure 9 Anti-CD11d treatment improves cognitive performance in water maze in the long recovery period (8 weeks) after repeated
mild fluid percussion injury. Format of figure is identical to that of Figure 8 (n = 12/group). (A) Plot of search time vs. sequential trial during
acquisition training in the water maze test. (B) Plot of percent of direct and circle swims during acquisition training. (C) Plot of search time with
respect to number of trials (as in A) during reversal training. (D) Plot of percent of direct and circle swims during reversal training. *Different from
sham-injured group; #different from 1B7 group; for post hoc comparisons of means, all P ≤0.05. For additional statistical details see Results.

number of closed arm entries was used as a measure
of locomotion. During both SR and LR elevated-plus
maze testing the 1B7 group, but not the CD11d group,
spent less time in the open arms compared to the sham
group (SR: F2,43 = 3.283, P <0.05; LR: F2,35 = 3.459,
P <0.05, data not shown). The number of closed
arm entries did not differ between groups (all
P >0.05, data not shown).

Beam task

Traverse time and the number of slips and falls were used
as measures of sensorimotor ability on the beam task. The
SR groups did not differ in traverse times (P >0.05; data
not shown) or in the measure of slips and falls (P >0.05;
data not shown). However, in the LR condition the 1B7
group, but not the CD11d group, displayed significantly
more slips and falls than the sham group (F2,35 = 4.861,
P <0.05, data not shown).

Discussion
Neuroinflammation and tissue damage

Consistent with previous findings from our laboratory [5],
repeated mLFP in the rat induced a long-term neuroinflam
matory response involving increases in activated neutro
phils, microglia/macrophages, and astrocytes within the
injured brain. This response occurred concurrently with
increased lipid peroxidation, axonal injury, neuronal loss,
and behavioral impairments. The oxidative burst of acti
vated neutrophils and macrophages generates free radicals
that can lead to secondary CNS injury in the form of
peroxidation of lipid membranes [19,35,36]. The enzyme
MPO is part of the pathway that generates oxidative
stress via formation of hydrogen peroxide and other
oxidative molecules, and is present in large quantities
in granules within neutrophils and, to a lesser extent,
macrophages [37,38]. Activated astrocytes are also active
participants in neuroinflammation [39]. Astrocytes respond to a host of pro-inflammatory mediators released
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by activated leukocytes, and in turn release additional
cytokines that can regulate microglia, neurons, and other
astrocytes [40].
Anti-CD11d mAb treatment significantly reduced
activated neutrophils, macrophages, and astrocytes in
the SR condition relative to repeated mLFP rats treated
with a 1B7 control mAb. Analysis of neuronal loss, as
monitored by immunohistochemistry and western blot
analysis of brain homogenates, revealed a significant
increase in NeuN expression in the CD11d-SR rats
compared to the 1B7-SR rats. Additionally, analysis of
axonal injury, as monitored by immunohistochemical
and western blot analysis of the corpus callosum,
revealed a significant decrease in APP accumulation in the
CD11d-SR rats compared to the 1B7-SR rats. Reductions
in neuronal loss and axonal injury by anti-CD11d mAb
are both likely mechanisms for the behavioral recovery
associated with the treatment. As the anti-CD11d mAb
treatment also reduced MPO levels and lipid peroxidation
in the injured brain, oxidative stress and lipid peroxidation
appear to be key mechanisms of inflammatory-mediated
secondary damage and associated behavioral impairments
in repeated mLFP. We have previously reported that the
anti-CD11d treatment changes the nature of the cytokine/
chemokine response from a pro-inflammatory response to
a wound healing response when delivered acutely after
spinal cord injury [41]. Thus the reduced recruitment of
neutrophils and macrophages to the lesion site may have
led to altered levels of cytokine and chemokine production
at the lesion and consequently to reduced levels of
leukocyte activation and immune-mediated tissue damage.
At 8 weeks post-injury, the anti-CD11d mAb-treated rats
continued to exhibit significant reductions in astrogliosis,
axonal injury, and behavioral impairments relative to
1B7-treated rats. However, the anti-CD11d mAb-treated
rats were impaired relative to sham controls on some behavioral measures, and exhibited significant neuronal loss,
axonal injury, and lipid peroxidation. As the anti-CD11d
treatment reduced but did not completely prevent neutrophil and macrophage infiltration of the injured brain, a
small inflammatory response may have led to these effects.
As the current study is the first to use the anti-CD11d
mAb in the complex pathophysiological setting of repeated
concussion, the treatment regimen applied may not have
been optimal, generating a less robust outcome than may
be possible. Other mechanisms of secondary injury are also
likely to contribute to the pathology of repeated concussion
and might account for some of the detrimental effects
observed here [10]. Nonetheless, anti-CD11d mAb treatment at 2 h and 24 h after each of three mLFP significantly
reduced neuroinflammation, lipid peroxidation, neuronal
loss, axonal injury, and behavioral impairments, indicating
that neuroinflammation may be a key contributor to secondary damage in repeated concussions and associated
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neurodegenerative conditions such as chronic traumatic
encephalopathy.
Behavioral outcome

The anti-CD11d mAb treatment improved cognitive
function following repeated concussion, as CD11d rats
outperformed 1B7 rats in the water maze. During the SR
condition, the CD11d rats displayed no impairments in the
water maze compared to sham-injured rats and performed
better than the 1B7 rats on all measures. Consistent with
previous findings from our laboratory, long-term cognitive
impairments were present in rats with repeated concussion
at 8 weeks post-injury relative to sham controls [5], regardless of treatment. However, the CD11d rats continued to
outperform the 1B7 rats, requiring significantly less time to
locate the hidden platform during both acquisition and
reversal compared to the 1B7 group.
The 1B7-treated rats also displayed a significant
increase in anxiety-like behavior in both the SR and LR
conditions as they spent significantly less time in the
open arm of the elevated-plus maze compared to the
sham controls [32,42], while the CD11d-treated groups
did not [5]. These findings are consistent with previous
findings from our laboratory indicating that repeated
mLFP increase anxiety-like behavior, and that the antiCD11d mAb treatment reduces the development of
anxiety in rats after TBI [18].
The 1B7-LR group also exhibited significantly more
slips and falls on the beam task compared to sham-LR
rats, while the CD11d-LR group did not. These findings are
consistent with previous findings from our laboratory indicating that anti-CD11d mAb treatment preserves motor
function following TBI [18]. The finding that the 1B7 group
displayed deficits on the beam task in the LR condition
suggests that locomotor ability should be considered when
interpreting water maze and elevated-plus maze results.
However, although 1B7 rats displayed increased slips and
falls in the LR condition, they were not impaired on the
measures of beam traverse times, swim speed in the water
maze, and the number of closed arm entries in the
elevated-plus maze, suggesting that the impairments
suffered by 1B7 rats represent a fine motor or gait deficit
rather than a gross motor abnormality [43]. Furthermore,
impairments in the water maze and elevated-plus maze also
occurred in the 1B7-SR group in the absence of any
evidence of motor abnormalities. Thus, it appears
unlikely that any motor impairments suffered by the
1B7 group directly accounted for the water maze and
the elevated-plus findings.
These results are similar to the findings of other studies
in which antibody treatments targeted the infiltration of
peripheral leukocytes after single severe TBI in rats
[18,23,44,45]. Specifically, we have previously reported
that anti-CD11d mAb treatment reduced leukocyte levels,
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astrocyte activation, lipid peroxidation, and neuronal
loss in a severely injured brain, and these changes
were accompanied by improved cognitive, emotional,
and sensorimotor outcomes relative to injured rats
treated with a control mAb [18,23]. Although key
methodological differences limit direct comparisons
between these experiments and the current study, it
is important to note that anti-CD11d mAb therapy
had similar benefits in both mild and severe TBI
settings. Furthermore, despite the overall reduction of
neutrophil and macrophage populations in the injured
brains, animals treated with anti-CD11d mAb do not
appear to suffer infections in the CNS or elsewhere [18].
This likely reflects the acute nature of the treatment schedule (i.e. completed by 48 h after each injury), thus limiting
the time window during which the anti-CD11d
mAb-treated rats might be more vulnerable to infection
due to compromised leukocyte trafficking [18].

Conclusions
Anti-CD11d mAb treatment reduced behavioral impairments, neuroinflammation, lipid peroxidation, neuronal
loss, and axonal injury in the rat mLFP model of
repeated concussion. At acute injury time-points, rats
treated with anti-CD11d mAb at 2 h and 24 h after each
of three repeated mLFP displayed significant reductions
in unconsciousness and self-righting reflex times, cognitive impairments, neutrophil and macrophage levels,
astrogliosis, lipid peroxidation, axonal injury, and neuronal loss compared to injured rats treated with a 1B7
control mAb. At the 8-week chronic injury time point,
injured rats treated with the anti-CD11d mAb continued
to exhibit reduced cognitive impairments as well as
diminished neuroinflammation, and axonal injury
relative to injured rats treated with 1B7 control mAb. In
addition, the 1B7-treated rats performed significantly
worse than sham-injured rats on behavioral tasks of
anxiety-like behavior and sensorimotor function, whereas
the anti-CD11d-treated rats did not. Although antiCD11d-treated rats displayed some evidence of cognitive
impairment, neuroinflammation, lipid peroxidation, neuronal loss, and axonal injury relative to sham-controls,
they demonstrated significantly better outcomes compared to control antibody-treated rats. Taken together,
these findings suggest that infiltrating leukocytes increase
neuroinflammation, secondary brain damage, and functional impairment in a repeated concussion setting, and
that the anti-CD11d mAb holds promise as a novel
treatment to limit these effects.
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